June 2018 | DelveInsight Business Research Skip to main content
delveinsight blog
  • ABOUT
    • About Us
    • Our Leadership
    • Our Clients
  • CAPABILITIES & SOLUTIONS
    • Reports
    • Competitive Intelligence
    • Case Study
  • CONSULTING SERVICE
  • REPORT STORE
  • MEDIA
    • Blog
    • Press Releases
    • White Papers / Newsletter
    • Events
  • CAREER
  • CONTACT US
  • Report Store

Month: June 2018

Jun 22 Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential

Fatty Acid Amide Hydrolase (FAAH) Inhibitor – an enzyme with novel therapeutic potential

Jun 22, 2018Jul 12, 2018 DelveInsight Leave a comment

Fatty acid amide hydrolase (FAAH) belongs to the serine hydrolase family of enzymes. The identification of this enzyme was led by the discovery and characterization of…

Read More
Jun 21 Hepatic Encephalopathy- An ailment of liver to brain

Hepatic Encephalopathy- An ailment of liver to brain

Jun 21, 2018Jul 12, 2018 DelveInsight Leave a comment

Hepatic Encephalopathy (HE) can be described as deterioration of brain function occurring due to accumulation of toxic substances in the blood which ultimately reach the brain….

Read More
Jun 18 NF-κB Inhibitors- A Promising Future

NF-κB Inhibitors- A Promising Future

Jun 18, 2018 DelveInsight Leave a comment

NF-κB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a protein transcription factor that can orchestrate complex biological processes such as cell survival, cytokine production, inflammatory…

Read More
Jun 14 Notizia

Notizia

Jun 14, 2018 DelveInsight Leave a comment

Idera’s dermatomyositis drug missed primary endpoint in phase 2 Idera’s toll-like receptor (TLR) antagonist, IMO-8400, failed to meet its primary endpoint in a phase 2 trial…

Read More
Jun 7 Notizia

Notizia

Jun 7, 2018 DelveInsight Leave a comment

Axovant rely on new gene therapy, Rise in Shares  Roivant Neuro Company has licensed Oxford Biomedica’s gene therapy OXB-102, now AXO-Lenti-PD, for Parkinson’s disease (PD). Spark…

Read More

Recent Posts

  • Acquisition of ArQule; Synthorx; and Zentalis nabs a raise
  • Are Rare diseases truly Rare?
  • Hype over Gene Therapy: Challenges and Opportunities
  • Reblozyl under FDA review; Audentes buyout & Tecentriq’s new approval
  • The Regulatory process for drug approval in the MENA region

Browse by Category

  • Anti-coagulants (8)
  • API Business Opportunity (5)
  • Articles (284)
  • Atrial Fibrillation (6)
  • Business Consultant (446)
    • Pharma Consultant (427)
  • Chimeric Antigen Receptor (CAR) T-cell Therapy (7)
  • CNS Indications (1)
  • CVS Indications (4)
  • DelveInsight's Drug Report (154)
  • DelveInsight's Indication Pipeline Reports (68)
  • DelveInsight's Oncology based Reports (46)
  • Gene Therapy Products (31)
  • Infographics (40)
  • new therapeutic target (5)
  • Newsletter (2)
  • Notizia (155)
  • Oncology based Indications (11)
  • Orphan market (4)
  • PD-1 and PD-L1 inhibitors (5)
  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (1)
  • Pulmonary arterial hypertension (1)
  • Rising of Orphan Drug Development (3)
  • Snippets (127)
  • Specialized Reports (15)
  • The Business Cocktail (139)
  • Uncategorized (61)
  • Venous Thromboembolism (3)

Archives

  • December 2019 (9)
  • November 2019 (24)
  • October 2019 (27)
  • September 2019 (23)
  • August 2019 (22)
  • July 2019 (25)
  • June 2019 (30)
  • May 2019 (29)
  • April 2019 (29)
  • March 2019 (27)
  • February 2019 (20)
  • January 2019 (18)
  • December 2018 (19)
  • November 2018 (26)
  • October 2018 (21)
  • September 2018 (20)
  • August 2018 (26)
  • July 2018 (13)
  • June 2018 (5)
  • May 2018 (8)
  • April 2018 (6)
  • March 2018 (14)
  • February 2018 (11)
  • January 2018 (15)
  • December 2017 (8)
  • November 2017 (13)
  • October 2017 (8)
  • September 2017 (14)
  • August 2017 (13)
  • July 2017 (9)
  • June 2017 (14)
  • May 2017 (20)
  • April 2017 (19)
  • March 2017 (24)
  • February 2017 (21)
  • January 2017 (23)
  • December 2016 (22)
  • November 2016 (23)
  • October 2016 (17)
  • September 2016 (21)
  • August 2016 (17)
  • May 2016 (4)
  • March 2016 (8)
  • February 2016 (3)
  • January 2016 (7)
  • November 2015 (1)
  • October 2015 (1)
  • September 2015 (2)
  • August 2015 (2)
  • July 2015 (8)
  • June 2015 (4)
  • May 2015 (1)
  • April 2015 (5)
  • March 2015 (6)
  • February 2015 (2)
  • January 2015 (5)
  • December 2014 (17)
  • November 2014 (2)
  • September 2014 (1)
  • August 2014 (7)
  • July 2014 (7)
delveinsight


Quick Links

  • About
  • Capabilities & Solutions
  • Report Store
  • Media
  • Career
  • Contact Us

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Tweets by @DelveInsight

Copyright © 2019 Delveinsight.

  • Sitemap
  • Terms & Conditions
  • Privacy policy